| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
For personalized chemotherapy in colorectal cancer (CRC), the relationship between plasma ratio of dihydrouracil (UH2)/uracil (Ura) and pharmacokinetics parameters of 5-FU was investigated to evaluate the usefulness as a surrogate marker of DPD activity in liver. Based on the pharmacokinetic parameters estimated from CRC rats, we developed a pharmacokinetic-pharmacodynamic (PK-PD) model with plasma UH2/Ura ratio for predicting the tumor growth in CRC rats. Before 5-FU treatment, the measurement of UH2/Ura values as a surrogate biomarker of DPD activity in liver could predict tumor growth in CRC rats. Besides, the UH2/Ura ratio in plasma could be useful for the optimized dosage regimen for CRC chemotherapy. These findings would be cost-effective and helpful for personalized anti-cancer treatment
|
